INT77307

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.77
First Reported 1998
Last Reported 2011
Negated 11
Speculated 12
Reported most in Body
Documents 399
Total Number 414
Disease Relevance 319.77
Pain Relevance 38.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Bcl2) cell morphogenesis (Bcl2) endoplasmic reticulum (Bcl2)
intracellular (Bcl2) cytoplasm (Bcl2) cell proliferation (Bcl2)
Anatomy Link Frequency
brain 10
B cells 10
MDA-MB-453 9
lung 8
neutrophils 7
Bcl2 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 2768 100.00 Very High Very High Very High
ischemia 326 100.00 Very High Very High Very High
rheumatoid arthritis 432 99.84 Very High Very High Very High
Morphine 260 99.84 Very High Very High Very High
agonist 373 99.78 Very High Very High Very High
Paracetamol 144 99.78 Very High Very High Very High
COX-2 inhibitor 438 99.60 Very High Very High Very High
COX2 98 99.34 Very High Very High Very High
antagonist 175 99.28 Very High Very High Very High
qutenza 62 99.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Apoptosis 14842 100.00 Very High Very High Very High
INFLAMMATION 3094 100.00 Very High Very High Very High
Targeted Disruption 2072 100.00 Very High Very High Very High
Injury 1500 100.00 Very High Very High Very High
Lymphatic System Cancer 1186 100.00 Very High Very High Very High
Cv Unclassified Under Development 315 100.00 Very High Very High Very High
Prostate Cancer 274 100.00 Very High Very High Very High
Leukemia 207 100.00 Very High Very High Very High
Renal Cancer 72 100.00 Very High Very High Very High
Retinoblastoma 53 100.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Several studies indicate that overexpression of Bcl-2 inhibits apoptosis induced by anticancer drugs, radiation, and other DNA-damaging agents [9,10].
Gene_expression (overexpression) of Bcl-2 associated with apoptosis
1) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.94 Pain Relevance 0
These findings suggest that the downregulation of Bcl-2 expression by AS Bcl-2 enhances drug sensitivity by modulating the apoptotic signal transduction pathway of Bcl-2.
Gene_expression (expression) of Bcl-2 associated with apoptosis
2) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.72 Pain Relevance 0
Transfection of the bcl-2 gene into MDA-MB-453 cells decreased their sensitivity to DOX and MMC but not to taxanes such as TXL and TXT.
Gene_expression (Transfection) of bcl-2 in MDA-MB-453
3) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.44 Pain Relevance 0
The role of Bcl-2 in determining the chemosensitivity of breast cancer cells was tested in MDA-MB-453 cells expressing low levels of Bcl-2.
Gene_expression (expressing) of Bcl-2 in MDA-MB-453 associated with breast cancer
4) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.44 Pain Relevance 0
As shown in Fig. 6a, Bcl-2 expression was suppressed on day 4, and almost completely inhibited on day 15, after treatment with AS Bcl-2, which was given by intraperitoneal injection every other week for 4 weeks.
Gene_expression (expression) of Bcl-2
5) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.68 Pain Relevance 0
Bcl-2 expression is regulated by the ER-responsive element of the promoter region of the bcl-2 gene [26], such that overexpression of Bcl-2 might be expected to confer greater drug resistance on ER-positive breast cancer cells.
Gene_expression (expression) of Bcl-2 associated with breast cancer
6) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.68 Pain Relevance 0
The expression of Bcl-2 by MDA-MB-453 cells was determined by Western blotting with a monoclonal antibody against Bcl-2.


Gene_expression (expression) of Bcl-2 in MDA-MB-453
7) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0 Pain Relevance 0
As shown in Fig. 4, MDA-MB-453 cells were resistant to DOX and MMC after transfection with the bcl-2 gene (P < 0.05, Student's t-test), whereas drug sensitivity to taxanes was not changed.
Gene_expression (transfection) of bcl-2 in MDA-MB-453
8) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.21 Pain Relevance 0
Two other clones transfected with the bcl-2 gene had similar drug sensitivities to those of control cells transfected with vector alone (data not shown).


Gene_expression (transfected) of bcl-2
9) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.24 Pain Relevance 0
In fact, overexpression of Bcl-2 and Bcl-xL is observed in several cancers, including hematologic malignancies, as well as a range of solid tumors, including nasopharyngeal, colorectal, prostate, and breast cancer [5-7].
Gene_expression (overexpression) of Bcl-2 associated with cancer, breast cancer, solid tumor and hematologic neoplasms
10) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.87 Pain Relevance 0
Another influencing factor might be a difference in the ability of sequence-specific AS ODNs to suppress Bcl-2 and Bcl-xL expression.
Gene_expression (expression) of Bcl-2
11) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.54 Pain Relevance 0
Because the enforced overexpression of Bcl-2 can act as an antioxidant in response to DNA damage, the decreased chemosensitivity of the Bcl-2-transfected breast cancer cells to DNA-damaging agents, including DOX and MMC, may be explained by this effect.
Gene_expression (overexpression) of Bcl-2 associated with breast cancer
12) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.39 Pain Relevance 0
Bcl-2 expression is regulated by the ER-responsive element of the promoter region of the bcl-2 gene [26], such that overexpression of Bcl-2 might be expected to confer greater drug resistance on ER-positive breast cancer cells.
Gene_expression (overexpression) of Bcl-2 associated with breast cancer
13) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.66 Pain Relevance 0
Given that Bcl-2 and Bcl-xL are capable of inhibiting anticancer drug-induced apoptosis, which is mediated by the voltage-dependent anion channel (VDAC) in the outer mitochondrial membrane, overexpression of Bcl-2 and Bcl-xL might confer resistance to chemotherapy [4].
Gene_expression (overexpression) of Bcl-2 associated with apoptosis
14) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.85 Pain Relevance 0
As shown in Fig. 5, treatment with AS Bcl-2 and DOX markedly suppressed Bcl-2 expression from that observed after treatment with DOX alone.
Gene_expression (expression) of Bcl-2
15) Confidence 0.77 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1410745 Disease Relevance 0.47 Pain Relevance 0
The aim of this study was to determine if NSAID-induced regression of intestinal adenomas might be associated with changes in beta-catenin or Bcl-2 expression.
Gene_expression (expression) of Bcl-2 associated with adenoma and cinod
16) Confidence 0.75 Published 1999 Journal Carcinogenesis Section Abstract Doc Link 10223192 Disease Relevance 0.95 Pain Relevance 0.24
Colonic tumors expressed higher levels of Bcl-2 than those from the small intestine and did not show any significant changes in either Bcl-2 or beta-catenin expression after treatment.
Gene_expression (expression) of Bcl-2 in small intestine associated with cancer
17) Confidence 0.75 Published 1999 Journal Carcinogenesis Section Abstract Doc Link 10223192 Disease Relevance 0.68 Pain Relevance 0.16
Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice.
Gene_expression (expression) of Bcl-2 associated with intestinal cancer and cox2
18) Confidence 0.75 Published 1999 Journal Carcinogenesis Section Title Doc Link 10223192 Disease Relevance 0.80 Pain Relevance 0.31
Colonic tumors expressed higher levels of Bcl-2 than those from the small intestine and did not show any significant changes in either Bcl-2 or beta-catenin expression after treatment.
Gene_expression (expressed) of Bcl-2 in small intestine associated with cancer
19) Confidence 0.75 Published 1999 Journal Carcinogenesis Section Abstract Doc Link 10223192 Disease Relevance 0.76 Pain Relevance 0.16
Intestinal tumors from Min/+ mice were harvested after treatment with sulindac for 2, 4 or 20 days and evaluated for expression of beta-catenin and Bcl-2 using immunohistochemistry.
Gene_expression (expression) of Bcl-2 associated with intestinal cancer
20) Confidence 0.75 Published 1999 Journal Carcinogenesis Section Abstract Doc Link 10223192 Disease Relevance 0.95 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox